Interventional therapy in malignant central airway tumors

Efficacy of intraluminal ablation versus stenting in central airway squamous cell carcinoma and adenoid cystic carcinoma: a randomized, open, controled, muti-center clinical study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12003102

Enrollment

Unknown

Registered

2012-11-16

Start date

2012-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant central airway tumor

Interventions

ablation plus basic therapy:ablation plus basic therapy

stenting plus basic therapy:stenting plus basic therapy

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) 18-70 years; 2) ECOG 2-4 scores; 3) Pathologically and/or cytologically diagnosed as III/IV stage tracheal/bronchial squamous cancer or adenoid cystic carcinima; 4) Aiway obstruced to 30% by lesion type including intrallunminal, tubal and mixed; 5) Life expectancy more than 3 months; 6) Two weeks of eluting time for patients who have been undervent chemotherapy. After the procedure pt. can be treated by chemotherapy(refer to chemo-group of this study); 7) No radiation herapy in the past and can accept radiation after the procedure; 8) Patients who understand the informed consent of this study and signed.

Exclusion criteria

Exclusion criteria: 1) Too severe to accept bronchoscopy; 2) Have been undervent radiation therapy or being in a therapy of radiation.

Design outcomes

Primary

Measure	Time frame
TTP (Time to progression);	—

Secondary

Measure	Time frame
Qulity of life;	—

Countries

China

Contacts

Public ContactWang Hongwu

wanghongwu2008@yahoo.cn+86 010-64667755-2277

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026